Datasite partners with Prudentia Sciences to accelerate life sciences diligence. Prudentia Sciences [email protected] Secure Datasite data room access meets AI-powered scientific diligence to help life sciences dealmakers move faster. MINNEAPOLIS, Minn. - Oct. 29, 2026 - Datasite, the essential infrastructure for mergers and acquisitions (M&A), today announced a partnership with Prudentia Sciences, a pioneer in AI-native dealmaking technology for life sciences. The partnership connects approved transaction materials in Datasite data rooms with Prudentia's AI-powered scientific diligence workflows. Life sciences transactions require buyers and investors to assess clinical evidence, mechanism of action, development stage, regulatory pathway, competitive landscape, and scientific risk under compressed timelines, while innovators need to protect sensitive transaction materials. By connecting Prudentia Sciences with Datasite, dealmakers can bring approved deal documents into Prudentia's review environment, where expert-developed frameworks help accelerate evidence-based assessments while preserving existing access controls. The result is a faster path from document review to diligence decisions, without requiring innovators to change how they manage transaction materials. Through the connection, users can: * Link an existing Datasite data room to Prudentia's diligence environment; * Manage and control access to data; and * Help prevent customer data from being used to train AI models. This connection also allows users to significantly accelerate the diligence process, leading to faster, more evidence-based decisions. "Life sciences diligence is exceptionally challenging," said Nicholas Renter, Senior Vice President, Strategic Growth & Partnerships at Datasite. "By connecting Datasite data rooms with Prudentia's scientific intelligence, we're helping life sciences dealmakers evaluate complex assets faster while keeping sensitive transaction information protected." "Turning complex scientific evidence into clear conviction is a critical step in life sciences deal diligence," said Sadiqa Mahmood, Founder and CEO of Prudentia Sciences. "With Datasite, we can give innovators a secure way to share their data and enable buyers and investors to quickly evaluate assets." This partnership is part of Datasite's growing ecosystem of partner solutions that extend its secure deal infrastructure across the investment lifecycle. The Prudentia Sciences partnership adds specialized diligence capabilities for buyers, investors, and innovators evaluating pharmaceutical and biotech assets. About Datasite Datasite is the essential infrastructure for M&A. It helps companies, investors, and advisors find opportunities, manage complex transactions, and make better decisions. Products include market intelligence, secure data rooms, and digital boardrooms, assisted by a team of global experts available 24/7. Native AI flows through these capabilities to help dealmakers inform strategy, transact efficiently, and decide with confidence. With more than 50 years of experience, Datasite delivers many of the world's largest and most complex deals. Learn more at www.datasite.com. About Prudentia Sciences Prudentia Sciences provides an AI-native platform that enables pharmaceutical companies, biotechnology companies, and financial institutions to securely evaluate life sciences assets with greater speed and rigor. By synthesizing complex clinical signals into actionable insights, Prudentia accelerates deal throughput and provides strategic support for acquisition, licensing, and investment decisions made by business development, investment, and diligence teams. For more information, visit www.prudentiasciences.com.

Prudentia Sciences announces Series A led by McKesson Ventures, accelerating due diligence for life sciences dealmaking. Prudentia Sciences Prudentia Sciences, a pioneer in AI-native due diligence for life sciences dealmaking, today announced that it has secured $20 million in Series A financing. The round was led by McKesson Ventures with participation from SignalFire. Existing investors include Iaso Ventures, Virtue and GV. This brings the company's total funding to $27 million, following a $7 million seed round in 2024. Prudentia Sciences provides an AI-native platform that enables pharma companies, biotechs, and financial institutions to evaluate breakthrough medicines with unprecedented speed and rigor. By synthesizing complex clinical signals into actionable insights, Prudentia accelerates deal throughput and provides strategic leverage for acquisition, licensing, or investment decisions made by business development, investment, and diligence teams. The company's human-in-the-loop approach orchestrates seamless collaboration between buyers, sellers, and intermediaries. This ensures a secure, compliant infrastructure for the industry's most critical investment decisions. "Prudentia is modernizing the way life sciences organizations harness data to evaluate assets and proactively manage risk," said Dave Schulte, President, McKesson Ventures. "Their AI-native platform accelerates scientific due diligence with real-time insights, seamless integration, and intelligent automation - transforming a traditionally fragmented process into a connected, agile, and future-ready workflow." With this new capital, Prudentia Sciences will expand product capabilities, deepen intelligence for both technical and non-technical diligence, and scale commercial operations, including expansion to the Asia-Pacific and Europe. Prudentia creates a single, continuously updated source of truth for diligence, allowing teams to align faster and make high-stakes investment and partnering decisions with confidence with fully explainable AI. "Life sciences dealmaking is inherently complex and time-intensive, with substantial capital and scientific innovation at stake," said Sadiqa Mahmood, Founder and CEO of Prudentia Sciences. "Biotechs struggle to present their assets with clarity and rigor, while pharma teams are forced to balance speed with thorough diligence. Without an intelligent platform to bridge this gap, diligence remains fragmented and high-risk. Prudentia collapses the distance between technical data and strategic conviction, enabling teams to make confident go-or-no-go decisions in a fraction of the time." For more information, visit www.prudentiasciences.com. View source version on businesswire.com: https://www.businesswire.com/news/home/20260106972777/en/